enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada. Show more

4868 Rue Levy, Montreal, QC, H4R 2P1, Canada

Biotechnology

Healthcare

Market Cap

483.3M

52 Wk Range

$2.65 - $12.25

Previous Close

$7.22

Open

$7.19

Volume

193,056

Day Range

$7.10 - $7.48

Enterprise Value

240.8M

Cash

275.9M

Avg Qtr Burn

-28.9M

Insider Ownership

0.09%

Institutional Own.

97.92%

Qtr Updated

01/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Detalimogene (EG-70) Details Non-Muscle Invasive Bladder Cancer (NMIBC)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.